NervGen Pharma Management
Management criteria checks 2/4
NervGen Pharma's CEO is Mike Kelly, appointed in Apr 2023, has a tenure of 2.08 years. total yearly compensation is CA$1.11M, comprised of 70.3% salary and 29.7% bonuses, including company stock and options. directly owns 0.2% of the company’s shares, worth €429.21K. The average tenure of the management team and the board of directors is 1.7 years and 4.3 years respectively.
Key information
Mike Kelly
Chief executive officer
CA$1.1m
Total compensation
| CEO salary percentage | 70.28% |
| CEO tenure | 2.1yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1.7yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -CA$26m |
| Dec 31 2024 | CA$1m | CA$781k | -CA$24m |
| Sep 30 2024 | n/a | n/a | -CA$24m |
| Jun 30 2024 | n/a | n/a | -CA$23m |
| Mar 31 2024 | n/a | n/a | -CA$20m |
| Dec 31 2023 | CA$740k | CA$540k | -CA$22m |
Compensation vs Market: Mike's total compensation ($USD798.73K) is about average for companies of similar size in the German market ($USD817.13K).
Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.
CEO
Mike Kelly (59 yo)
Mr. Michael P. Kelly, also known as Mike, has been President of U.S. Operations at Adapt Pharma since April 11, 2016. Mr. Kelly has responsibility for all of Adapt Pharma's U.S. operating activities.He ha...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 2.1yrs | CA$1.11m | 0.20% € 429.2k | |
| Co-Founder & Advisor | no data | no data | no data | |
| Co-Founder & Independent Director | no data | no data | 1.59% € 3.4m | |
| CFO & Corporate Secretary | 5.3yrs | CA$483.68k | 0.22% € 464.6k | |
| Chief Medical Officer | 4yrs | CA$767.90k | no data | |
| Co-Founder & Advisor | no data | no data | no data | |
| Senior Vice President of Technical Operations | 1.3yrs | no data | no data | |
| Senior Vice President of Corporate Development & Strategy | less than a year | no data | no data | |
| Senior Vice President of Program Management | 1.3yrs | no data | no data |
Experienced Management: 9UA's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 2.1yrs | CA$1.11m | 0.20% € 429.2k | |
| Co-Founder & Independent Director | 8.3yrs | no data | 1.59% € 3.4m | |
| Co-Founder & Advisor | no data | no data | no data | |
| Chairman | 3.7yrs | no data | 0.082% € 174.4k | |
| Independent Director | 7yrs | no data | 0.37% € 790.1k | |
| Independent Director | 4.6yrs | no data | 0.014% € 29.8k | |
| Member of Alzheimer's Disease Scientific Advisory Board | 4.3yrs | no data | no data | |
| Co-Inventor & Scientific Advisor | no data | no data | no data | |
| Member of Alzheimer's Disease Scientific Advisory Board | 4.3yrs | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Member of Alzheimer's Disease Scientific Advisory Board | 4.3yrs | no data | no data | |
| Advisor | 4.6yrs | no data | no data |
Experienced Board: 9UA's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 04:35 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NervGen Pharma Corp. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chelsea Stellick | iA Capital Markets |
| Scott McAuley | Paradigm Capital, Inc. |
| Michael Freeman | Raymond James Ltd. |